Old Couples holding hands and looking eachother

<span style="display: block; margin-top: 60px;">Trurapi<sup>®<span style="color: black;">▼</span></sup><span style="font-size: 0.6em; display: block; margin: 5px 0;">(Insulin aspart 100 units/mL)</span></span>

Insulin Trurapi (Insulin aspart 100 units/mL)

The first rapid acting insulin biosimilar of NovoRapid® approved in the UK and EU1

Trurapi 100 units/ml solution pen for injection

Trurapi® was granted marketing authorization in the United Kingdom and is anticipated to be available to prescribe in England, Scotland and Wales in July.

30% lower NHS list price vs. NovoRapid

30% lower NHS list price vs. NovoRapid2

1:1 unit dosing

1:1 initial unit dosing - available in the SoloStar pen and cartridges1, 3-4

*When transferring from other insulin products, dose adjustment of Trurapi® or basal insulin may be needed. Insulin aspart has a faster onset and shorter duration of action than soluble human insulin. Close glucose monitoring during transfer and initial weeks is recommended.1

Similar PK/PD profile

Similar PK/PD profile (T1DM), efficacy, safety and tolerability (T1DM and T2DM)3-4

Diabetes Stories

Learn from other payors, consultants and diabetes specialist nurses how they adopted a rapid acting insulin biosimilar in their region.

These videos are related to HCPs sharing their experiences with a different rapid acting insulin biosimilar.

Go to overview

Photo of Dr Duncan Browne

Dr Duncan Browne

Consultant Endocrinologist and Researcher Royal Cornwall Hospitals NHS Foundation Trust

Photo of Amanda Veall

    Amanda      Veall

Diabetes Specialist Nurse Cornwall Partnership NHS Foundation Trust

Photo of Marcus Jones

    Marcus     Jones

Formulary Pharmacist Gloucestershire Hospitals NHS Foundation Trust

Switch HCP
Start and switch

Find useful resources such as formulary FAQ, leave pieces and videos for payors and healthcare professionals to support a positive rapid acting insulin biosimilar adoption

Abbreviations:
EU, European Union; FAQ, frequently asked questions; NHS, National Health Service; PD, pharmacodynamic; PK, pharmacokinetic; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; UK, United Kingdom.

References:

  1. Trurapi SmPC (April 2021)
  2. Data on File, MAT-GB-2101599 (v1.0) April 2021
  3. Kapitza C, et al. Diabetes Technol Ther. 2020;22(4):278–284.
  4. Garg SK, et al. Diabetes Technol Ther. 2020;22(2):85–95.
This site uses cookies to store information on your computer. Some cookies on this site are needed because the site won’t work as expected without them. To learn more about cookies, please read our Cookie Policy.
By closing this message or using the website, you agree to our use of cookies on this device in agreement with our Cookie Policy, unless you have turned them off.
Accept and close